Our immune system has the ability to detect and fight infectious pathogens. It can also detect when normal cells become cancerous and kill those cells, preventing cancer progression. But over time, cancers can evolve and evade the immune response.
Researchers have been investigating several potential avenues to counter tumor immunosuppression and re-activate the immune system. One of these is chimeric antigen receptor (CAR) T-cell therapy, which is designed to harness the potent cytotoxicity of T cells by re-engineering their surface receptors to recognize and attack tumors.
Part One: What Are CAR-T Cells & How Are They Engineered?
Part Two: Research Challenges for Engineering CAR-T Cells
Additional Engineered CAR Resources for Your Research
- Resource Center: CAR-Engineered Cell Characterization Solutions
- Blog: CAR T Cell Detection: Anti-CAR Linker Antibodies for Whitlow/218 & G4S
- Blog: Spatial Insights for CAR-Engineered Cells in Solid Tumors: Antibody-Based CAR Detection Method
- Webinar: Novel Antibodies for the Characterization of CAR-T Cells
